Suggested remit: To appraise the clinical and cost effectiveness of durvalumab within its marketing authorisation for induction and maintenance treatment of untreated advanced or recurrent endometrial cancer.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6317

Provisional Schedule

Committee meeting: 1 04 March 2025
Expected publication 21 May 2025

Project Team

Project lead Jeremy Powell

Email enquiries

External Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ

Stakeholders

Companies sponsors AstraZeneca (durvalumab, olaparib)
Others Department of Health and Social Care
  NHS England
Patient carer groups Black Health Agency for Equality
  Cancer Black Care
  Cancer Equality
  Cancer 52
  Endometriosis Foundation
  Eve Appeal
  Go Girls
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Peaches Womb Cancer Trust
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  Wellbeing of Women
  Womb Cancer Support UK
  Women’s Health Concern
Professional groups Association of Anaesthetists
  Association of Cancer Physicians
  Association of Surgeons of Great Britain and Ireland
  British Association of Surgical Oncology
  British Geriatrics Society
  British Gynaecological Cancer Society
  British Institute of Radiology
  British Oncology Pharmacy Association
  British Psychosocial Oncology Society
  British Society for Clinical Cytology
  British Society for Colposcopy and Cervical Pathology
  Cancer Research UK
  National Forum of Gynaecological Oncology Nurses
  Royal College of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Obstetricians and Gynaecologists
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Accord (carboplatin, paclitaxel, cisplatin, doxorubicin)
  Alliance Healthcare (cisplatin, cyclophosphamide, paclitaxel)
  Bausch & Lomb (megestrol acetate)
  Baxter Healthcare (cyclophosphamide)
  Bristol Myers Squibb Pharmaceuticals (paclitaxel)
  Consilient Health (carboplatin)
  Fresenius Kabi (carboplatin, paclitaxel)
  Hospira UK (carboplatin, paclitaxel)
  Medac GmbH (doxorubicin)
  Pfizer (carboplatin, paclitaxel, cisplatin,
  doxorubicin, medroxyprogesterone
  acetate)
  Sandoz (cisplatin, cyclophosphamide)
  Seacross Pharmaceuticals (paclitaxel, doxorubicin)
  Teva UK (carboplatin, cisplatin, paclitaxel)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Genomics England
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
30 July 2024 Invitation to participate
25 March 2024 - 10 April 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6317
24 January 2024 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late July 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
08 December 2023 - 15 January 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6317
08 December 2023 In progress. Scoping commencing
02 May 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual